ReCode Therapeutics Appoints Julie Eastland as Chief Operating Officer and Chief Financial Officer
- Veteran life sciences executive brings over 25 years of biotechnology, financial and operations expertise
MENLO PARK, Calif. & DALLAS--(BUSINESS WIRE)-- ReCode Therapeutics™ (ReCode) (the Company), a private biopharmaceutical company pioneering disease-modifying medicines for the treatment of life-limiting respiratory diseases, today announced the appointment of Julie Eastland as chief operating officer (COO) and chief financial officer (CFO). Eastland will oversee the company’s financial and business operations.
“Julie has a demonstrated track record of steering both private and public life sciences companies through important milestones,” said David Lockhart, Ph.D., CEO and president, ReCode Therapeutics. “Her deep financial acumen, strong operations background and capital markets expertise will serve us well as we build a robust pipeline of treatments that target the underlying genetic cause of severe respiratory diseases. We’re thrilled to welcome Julie to ReCode as we continue to build our leadership team.”
Ms. Eastland is a seasoned strategic and financial executive with more than 25 years of experience in corporate finance, corporate development, financial planning and analysis, investor relations and operations. She previously served as chief financial officer and chief business officer of Rainier Therapeutics, a private biopharmaceutical company focused on developing treatments for bladder cancer. Prior to Rainier, Eastland served as chief financial officer and chief business officer of Cascadian Therapeutics, a publicly traded oncology company that was acquired by Seattle Genetics in 2018. While at Cascadian, Eastland was instrumental in the negotiation and sale of the company, primarily for its product tucatinib, a HER2 targeted breast cancer therapy now marketed as Tukysa®. Before Cascadian, she served as chief financial officer and vice president of operations at VLST Corporation, a private biotechnology company, and also held financial and strategic management positions of increasing responsibility at Dendreon and Amgen. Eastland received an M.B.A. from Edinburgh University Management School and a B.S. in finance from Colorado State University. Eastland serves on the board of directors for Dynavax Technologies (Nasdaq: DVAX), Graybug Vision (Nasdaq: GRAY) and Harpoon Therapeutics (Nasdaq: HARP).
About ReCode Therapeutics
ReCode Therapeutics is an integrated genetic medicines company developing targeted, disease-modifying therapies for patients with life-limiting respiratory diseases. The Company’s diverse pipeline includes lead programs for cystic fibrosis (CF) caused by nonsense mutations, and primary ciliary dyskinesia (PCD). ReCode has developed a non-viral delivery therapeutic platform that enables it to precisely deliver its medicines safely and effectively. The Company is leveraging its lipid nanoparticle and nucleic acid technologies across multiple modalities, including mRNA-mediated replacement therapies, first-in-class tRNA NanoCorrectors for diseases caused by nonsense mutations, and gene editing. For more information, visit www.recodetx.com
Steve E. Kunszabo
Source: ReCode Therapeutics